DOCSLIB.ORG

Grading Astrocytoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Grading Astrocytoma DIFFUSE GLIOMAS Precursor cell Precursor cell IDH1/2 mutation EGFR amplification/mutation G-CIMP NF1 loss/mutation PIK3R1/PIK3CA muttation WHO 2016 classification of primary brain PTEN loss/mutation TP53 mutation 1p/19q co-deletion TP53 loss ATRX mutation TERT promoter mutation tumors CDK2NA loss CDKN2B loss Felice Giangaspero RB1loss/mututaion CDK4 amplification Grade II-III TERT promoter mutation Grade II-III astrocytoma oligodendroglioma Grade II-III RB1 loss/mutation CDKN2A loss Astrocytoma wt CDk4/6 amplification PDGFRA amplification IDH-wt glioblastoma IDH-mut glioblastoma (grade IV) (grade IV) Major changes in the 2016 CNS WHO Diffuse Gliomas WHO 4 Ed. 2007 WHO 4 Ed.+ 2016 • Formulating concept of how CNS tumor diagnoses are structured in the Diffuse astrocytoma, IDH-1 mutant (II) Diffuse astrocytoma, (II) Gemistocytic astrocytoma, IDH-mutant (II) molecular era Fibrillary astrocytoma Diffuse astrocytoma, IDH-wildtype (II) Gemistocytic astrocytoma Diffuse astrocytoma,NOS (II) • Major restructuring of medulloblastomas, with incorporation of genetically Protoplasmatic astrocytoma defined entities Anaplastic astrocytoma, IDH-mutant (III) Anaplastic astrocytoma, (III) Anaplastic astrocytoma, IDH-wildtype (III) • Major restructuring of diffuse gliomas, with incorporation of genetically Anaplastic astrocytoma, NOS (III) defined entities Glioblastoma, (IV) Giant cell glioblastoma Glioblastoma, IDH-wildtype (IV) • Major restructuring of other embryonal tumors, with incorporation of genetically defined Gliosarcoma Giant cell glioblastoma (IV) entities and removal of the term “primitive neuroectodermal tumor” Gliomatosis cerebri Gliosarcoma (IV) Epithelioid glioblastoma (IV) • Novel approach distinguishing pediatric look-alikes, including designation of Glioblastoma, IDH-mutant (IV) Glioblastoma, NOS (IV) novel, genetically defined entity Oligodendroglioma, (II) • Addition of newly recognized entities, variants and patterns Anaplastic oligodendroglioma, (III) Diffuse midline glioma, H3 K27M-mutant (IV) • Diffuse midline glioma, H3 K27M–mutant (entity) Oligoastrocytoma, (II) Oligodendroglioma, IDH-mutant and 1p/19q-co-deleted (II) • Embryonal tumour with multilayered rosettes, C19MC-altered (entity) Anaplastic oligoastrocytoma, (III) Oligodendroglioma, NOS (II) • Ependymoma, RELA fusion–positive (entity) Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted (III) • Diffuse leptomeningeal glioneuronal tumor (entity) Anaplastic oligodendroglioma, NOS (III) • Anaplastic PXA (entity) Oligoastrocytoma (II) Anaplastic oligoastrocytoma (III) Acta Neuropathol. 2016;131:803-20 Useful markers for an integrated diagnosis in diffuse gliomas DIFFUSE GLIOMAS • IDH: IHC/Seq • ATRX:IHC • 1p/19q codeletion: FISH/ aCGH/CNV • TP53:IHC/Seq • TERT :Seq • H3.3K27 (pedGBM):IHC/Seq Integrated Diagnosis by IHC 1p-19q co-deletion IDH1 ATRX Diffuse astrocytoma (grade II) IDH1 mutated ATRX mutated Diffuse Astrocytoma (grade II WHO) Female 27 yrs IDH1 R132H IDH2 MUTATION R172G (A>G) ATRX p53 Frequency of specific IDH mutations in gliomas Age distribution of IDH mutations Lai et al. JCO, 2011 Anaplastic Astrocytoma (grade III WHO) Male 13 yrs Characteristics of H3 K27-mutant gliomas in adults IDH1 R132H Meyronet et al. Neuro-Oncol 2017, 19:1127-1134 Histone and chromatin modifier mutations High Grade Gliomas H3- G34 Mutated in pHGG and DIPG ATRX p53 H3F3A G34R GLY ARG 15 years old boy Jones C, Baker SJ, Nat Rev Cancer. 2014, 14 (10) Diffuse Midline Glioma, H3 K27M–mutant Imaging of High Grade Gliomas H3- G34 Mutated DIPG $$*ĺ$7*lysine ĺmethionine) Vettermann et al. Clin Nucl Med 2018, 43:895-898 anti-H3K27M (#ABE419 Millipore DIFFUSE GLIOMAS Mutational landscape in grade II and III gliomas Precursor cell Precursor cell IDH1/2 mutation EGFR amplification/mutation G-CIMP NF1 loss/mutation PIK3R1/PIK3CA muttation PTEN loss/mutation TP53 mutation 1p/19q co-deletion TP53 loss ATRX mutation TERT promoter mutation CDK2NA loss CDKN2B loss RB1loss/mututaion CDK4 amplification Grade II-III TERT promoter mutation Grade II-III astrocytoma oligodendroglioma Grade II-III RB1 loss/mutation CDKN2A loss Astrocytoma wt CDk4/6 amplification PDGFRA amplification IDH-wt glioblastoma IDH-mut glioblastoma Suzuki et al. Nature Genetics 2015 (grade IV) (grade IV) 1RYHOLPSURYHGJUDGLQJV\VWHP V IRU INFILTRATIVE ASTROCYTOMA IDH-PXWDQWDVWURF\WLFJOLRPDV Histological Parameters for Grading Nuclear Mitoses Vascular Necrosis atypia prolif. Grade III Grade IV Grade IV Grade II Shirahata et al. Acta Neuropathol 2018, 136:153-166 Mutational landscape in grade II and III gliomas Diffuse Astrocytoma (Grade II WHO) IDH WT 50 yrs M Molecular features of GBM (Grade IV) Suzuki et al. Nature Genetics 2015 EGFR Ampl 10q - Gain 7 IDHwt diffuse astrocytoma stratified for combinations of alterations of chromosomes 7 and 10. cIMPACT-NOW Grade II-III (A-AA) Grade IV (GBM) (Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy—Not Official WHO) To provide guidelines between WHO updates and to facilitate future WHO classification updates Stichel et al. Acta Neuropathol 2018 F,03$&7-NOW Adult IDH WT lower grade gliomas stratification recommended GLDJQRVWLF criteria IRU³'LIIXVHastrocytic JOLRPD IDH-wildtypeZLWKmolecular IHDWXUHV RIJOLREODVWRPD:+2 JUDGH,9´ 1. EGFR amplification OR 2. Combined whole chromosome 7 gain and whole FKURPRVRPHORVV í OR 3. TERT promoter mutation Aibadula et al. Neuro- Oncology 19: 1327-37, 2017 Brat et al. Acta Neuropathol (2018) 136:805-810) 'LIIXVH$VWURF\WRPD,'+-:LOGW\SH$'LVVROYLQJ'LDJQRVLV LOW GRADE GLIOMAS/GLIONEURONAL TUMORS Hasselblatt et al. J Neuropathol Exp Neurol. 2018;77(6):422-425 Other Astrocytic Tumors Pilocytic astrocytoma GANGLIOGLIOMA Pilomyxoid astrocytoma Subependymal giant cell astrocytoma Pleomorphic xantoastrocytoma Anaplastic pleomorphic xantoastrocytoma* Other gliomas Chordoid glioma of the third ventricle Angiocentic glioma Astroblastoma Neuronal and mixed neuronal-glia tumors ABRESPONSE TO VEMURAFENIB AFTER 3 MS OF TREATMENT Dysembryoplastic neuroepithelial tumour Gangliocytoma Ganglioglioma Anaplastic ganglioglioma Dysplastic cerebellar gangliocytoma Papillary glioneuronal tumour Diffuse leptomeningeal glioneuronal tumor* 2016 4+ Edition Central neurocytoma BRAF mutation V600E (GTG/GAG) Cerebellar liponeurocytoma Paraganglioma From del Bufalo et al. J Transl Med 2014, 12: 356 LGG/GN TUMORS AS A MAPK PATHWAY DISEASE Other Astrocytic Tumors Pilocytic astrocytoma Pilomyxoid astrocytoma Subependymal giant cell astrocytoma Pleomorphic xantoastrocytoma Anaplastic pleomorphic xantoastrocytoma* Other gliomas Chordoid gliomaof the third ventricle Angiocentic glioma Astroblastoma Neuronal and mixed neuronal-glia tumors Dysembryoplastic neuroepithelial tumour Gangliocytoma Ganglioglioma Anaplastic ganglioglioma Dysplastic cerebellar gangliocytoma Papillary glioneuronal tumour Diffuse leptomeningeal glioneuronal tumor* 2016 4+ Edition Central neurocytoma Cerebellar liponeurocytoma Paraganglioma Distribution of LGG/GN histologies and molecular genetic alterations DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR by anatomic tumor location. (DLGNT) Syn Sturm et al. JCO -2377. Perilongo et al. Child’s Nerv Syst, 2002, 18: 505-12 BRAF alterations in DLGNT C11orf95-RELA IXVLRQV in supratentorial ependymoma Dodgshun et al. J Neurooncol 2016 Rodriguez et. Acta Neuropathol 2015 Parker M., et al. :Nature, 2014. 506(7489) C11orf95-RELA fusion: nuclear translocation of RELA with activation of NF-kB pathway EPENDYMOMAS EPENDYMAL TUMORS RELA fusion: IHC surrogates WHO 4 Ed. 2007 WHO 4 Ed.+ 2016 Subependymoma Subependymoma Myxopapillary Ependymoma Myxopapillary Ependymoma Ependymoma Ependymoma Cellular Cellular L1CAM Papillary Papillary Clear cell Clear cell Tanycytic Tanycytic Anaplastic Ependymoma Ependymoma RELA fusion positive Anaplastic Ependymoma NF-kB/p65 Intracranial EPN Subgroups Mack and 7D\ORUCurr Opin Oncol J Mol Med (2015) 93:1075–1084 0HGXOOREODVWRPD in adultsthey're not MXVWELJkids EMBRYONAL TUMORS Lassaletta & Ramaswamy Neuro Oncol 2016, 18:895.7 Embryonal tumors Medulloblastoma MAJOR CARACTERISTICS OF ADULT MB WHO 4 Ed. 2007 WHO 4 Ed.+ 2016 • 3 MOLECULAR VARIANTS SHH (62%) Medulloblastoma Medulloblastoma genetically defined Group 4 (28%) Desmoplastic/nodular MB WNT-activated WNT (10%) MBEN MB SHH-activated and TP53-mutant Anaplastic MB MB SHH-activated and TP53-wildtype Large cell MB MB non-WNT/non-SHH • SHH MB group 3 PATCH1 and SMO mutations MB group 4 No TP53 mutation Medulloblastoma histologically defined MB Classic • WNT MB Desmoplastic/nodular MBEN no better prognosis MB Large cell/anaplastic MB NOS Remke et al. J Clin Oncol 2011 Zhao et al. Neuro-Oncology 2016 HGGHG (31%) Embryonal tumors MNGM (1%) 61% EPNEP (5%) ATRTAT (4%) PINEALPI (2%) WHO 4 Ed. 2007 WHO 4 Ed.+ 2016 MBM (3%) CPCCP (1%) EEWSW (2%) PXAPX (1%) CNS PNET Embryonal tumour with multilayered EETMRT (11%) CNS Neuroblastoma rosettes C19MC-altered Non-neoplastic brain CNS Embryonal tumour with multilayered CNS-PNETNET 1 Ganglioneuroblastoma rosettes NOS n.323 Institutional % CNS embryonal tumors NOS Medulloepithelioma Medulloepithelioma diagnosis 15% Ependymoblastoma CNS neuroblastoma Atypical teratoid/rhabdoid CNS ganglioneuroblastoma tumor CNS embryonal tumour NOS Atypical teratoid/rhabdoid tumour CNSCNS NNB-FOXR2B-FOXR2 ((14%)14%) CNS embryonal tumour with rhabdoid CNSC HGNETHGNET-MN1T-MN1 ((3%)3%) 24% CNSC EFT-CICEFTT-CIC (4%) features CNSC HGNET-BCORHGNETT-BCOR ((3%)3%) 6WXUPHWDO&HOO– DNA Methylation Profiling WHO 2016: no CNS-PNETs anymore! A novel molecular tool •
Load more

Recommended publications
  • Risk Factors for Gliomas and Meningiomas in Males in Los Angeles County1
    [CANCER RESEARCH 49, 6137-6143. November 1, 1989] Risk Factors for Gliomas and Meningiomas in Males in Los Angeles County1 Susan Preston-Martin,2 Wendy Mack, and Brian E. Henderson Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles, California 90033 ABSTRACT views with proxy respondents, we were unable to include a large proportion of otherwise eligible cases because they were deceased or Detailed job histories and information about other suspected risk were too ill or impaired to participate in an interview. The Los Angeles factors were obtained during interviews with 272 men aged 25-69 with a County Cancer Surveillance Program identified the cases (26). All primary brain tumor first diagnosed during 1980-1984 and with 272 diagnoses had been microscopically confirmed. individually matched neighbor controls. Separate analyses were con A total of 478 patients were identified. The hospital and attending ducted for the 202 glioma pairs and the 70 meningioma pairs. Meningi- physician granted us permission to contact 396 (83%) patients. We oma, but not glioma, was related to having a serious head injury 20 or were unable to locate 22 patients, 38 chose not to participate, and 60 more years before diagnosis (odds ratio (OR) = 2.3; 95% confidence were aphasie or too ill to complete the interview. We interviewed 277 interval (CI) = 1.1-5.4), and a clear dose-response effect was observed patients (74% of the 374 patients contacted about the study or 58% of relating meningioma risk to number of serious head injuries (/' for trend the initial 478 patients).
    [Show full text]
  • Original Article Outcome of Supratentorial Intraaxial Extra Ventricular Primary Pediatric Brain Tumors
    Original Article Outcome of supratentorial intraaxial extra ventricular primary pediatric brain tumors: A prospective study Mohana Rao Patibandla, Suchanda Bhattacharjee1, Megha S. Uppin2, Aniruddh Kumar Purohit1 Department of Neurosurgery, Krishna Institute of Medical Sciences Secunderabad, Departments of 1Neurosurgery and 2Pathology, Nizam’s Institute of Medical Sciences, Hyderabad, Andhra Pradesh, India Address for correspondence: Dr. Mohana Rao Patibandla, Department of Neurosurgery, University of Colorado Denver, 13123, E 16th Ave, Aurora, CO 80045, USA. Email: [email protected] ABSTRACT Introduction: Tumors of the central nervous system (CNS) are the second most frequent malignancy of childhood and the most common solid tumor in this age group. CNS tumors represent approximately 17% of all malignancies in the pediatric age range, including adolescents. Glial neoplasms in children account for up to 60% of supratentorial intraaxial tumors. Their histological distribution and prognostic features differ from that of adults. Aims and Objectives: To study clinical and pathological characteristics, and to analyze the outcome using the Engel’s classification for seizures, Karnofsky’s score during the available follow‑up period of minimum 1 year following the surgical and adjuvant therapy of supratentorial intraaxial extraventricular primary pediatric (SIEPP) brain tumors in children equal or less than 18 years. Materials and Methods: The study design is a prospective study done in NIMS from October 2008 to January 2012. All the patients less than 18 years of age operated for SIEPP brain tumors proven histopathologically were included in the study. All the patients with recurrent or residual primary tumors or secondaries were excluded from the study. Post operative CT or magnetic resonance imaging (MRI) is done following surgery.
    [Show full text]
  • Charts Chart 1: Benign and Borderline Intracranial and CNS Tumors Chart
    Charts Chart 1: Benign and Borderline Intracranial and CNS Tumors Chart Glial Tumor Neuronal and Neuronal‐ Ependymomas glial Neoplasms Subependymoma Subependymal Giant (9383/1) Cell Astrocytoma(9384/1) Myyppxopapillar y Desmoplastic Infantile Ependymoma Astrocytoma (9412/1) (9394/1) Chart 1: Benign and Borderline Intracranial and CNS Tumors Chart Glial Tumor Neuronal and Neuronal‐ Ependymomas glial Neoplasms Subependymoma Subependymal Giant (9383/1) Cell Astrocytoma(9384/1) Myyppxopapillar y Desmoplastic Infantile Ependymoma Astrocytoma (9412/1) (9394/1) Use this chart to code histology. The tree is arranged Chart Instructions: Neuroepithelial in descending order. Each branch is a histology group, starting at the top (9503) with the least specific terms and descending into more specific terms. Ependymal Embryonal Pineal Choro id plexus Neuronal and mixed Neuroblastic Glial Oligodendroglial tumors tumors tumors tumors neuronal-glial tumors tumors tumors tumors Pineoblastoma Ependymoma, Choroid plexus Olfactory neuroblastoma Oligodendroglioma NOS (9391) (9362) carcinoma Ganglioglioma, anaplastic (9522) NOS (9450) Oligodendroglioma (9390) (9505 Olfactory neurocytoma Ganglioglioma, malignant (()9521) anaplastic (()9451) Anasplastic ependymoma (9505) Olfactory neuroepithlioma Oligodendroblastoma (9392) (9523) (9460) Papillary ependymoma (9393) Glioma, NOS (9380) Supratentorial primitive Atypical EdEpendymo bltblastoma MdllMedulloep ithliithelioma Medulloblastoma neuroectodermal tumor tetratoid/rhabdoid (9392) (9501) (9470) (PNET) (9473) tumor
    [Show full text]
  • Adrenal Neuroblastoma Mimicking Pheochromocytoma in an Adult With
    Khalayleh et al. Int Arch Endocrinol Clin Res 2017, 3:008 Volume 3 | Issue 1 International Archives of Endocrinology Clinical Research Case Report : Open Access Adrenal Neuroblastoma Mimicking Pheochromocytoma in an Adult with Neurofibromatosis Type 1 Harbi Khalayleh1, Hilla Knobler2, Vitaly Medvedovsky2, Edit Feldberg3, Judith Diment3, Lena Pinkas4, Guennadi Kouniavsky1 and Taiba Zornitzki2* 1Department of Surgery, Hebrew University Medical School of Jerusalem, Israel 2Endocrinology, Diabetes and Metabolism Institute, Kaplan Medical Center, Hebrew University Medical School of Jerusalem, Israel 3Pathology Institute, Kaplan Medical Center, Israel 4Nuclear Medicine Institute, Kaplan Medical Center, Israel *Corresponding author: Taiba Zornitzki, MD, Endocrinology, Diabetes and Metabolism Institute, Kaplan Medical Center, Hebrew University Medical School of Jerusalem, Bilu 1, 76100 Rehovot, Israel, Tel: +972-894- 41315, Fax: +972-8 944-1912, E-mail: [email protected] Context 2. This is the first reported case of an adrenal neuroblastoma occurring in an adult patient with NF1 presenting as a large Neurofibromatosis type 1 (NF1) is a genetic disorder asso- adrenal mass with increased catecholamine levels mimicking ciated with an increased risk of malignant disorders. Adrenal a pheochromocytoma. neuroblastoma is considered an extremely rare tumor in adults and was not previously described in association with NF1. 3. This case demonstrates the clinical overlap between pheo- Case description: A 42-year-old normotensive woman with chromocytoma and neuroblastoma. typical signs of NF1 underwent evaluation for abdominal pain, Keywords and a large 14 × 10 × 16 cm left adrenal mass displacing the Adrenal neuroblastoma, Neurofibromatosis type 1, Pheo- spleen, pancreas and colon was found. An initial diagnosis of chromocytoma, Neural crest-derived tumors pheochromocytoma was done based on the known strong association between pheochromocytoma, NF1 and increased catecholamine levels.
    [Show full text]
  • Ambient Mass Spectrometry for the Intraoperative Molecular Diagnosis of Human Brain Tumors
    Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors Livia S. Eberlina, Isaiah Nortonb, Daniel Orringerb, Ian F. Dunnb, Xiaohui Liub, Jennifer L. Ideb, Alan K. Jarmuscha, Keith L. Ligonc, Ferenc A. Joleszd, Alexandra J. Golbyb,d, Sandro Santagatac, Nathalie Y. R. Agarb,d,1, and R. Graham Cooksa,1 aDepartment of Chemistry and Center for Analytical Instrumentation Development, Purdue University, West Lafayette, IN 47907; and Departments of bNeurosurgery, cPathology, and dRadiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 Edited by Jack Halpern, The University of Chicago, Chicago, IL, and approved December 5, 2012 (received for review September 11, 2012) The main goal of brain tumor surgery is to maximize tumor resection at Brigham and Women’s Hospital (BWH), created an opportu- while preserving brain function. However, existing imaging and nity for collecting information about the extent of tumor resection surgical techniques do not offer the molecular information needed during surgery (5, 6). Although brain tumor resection typically to delineate tumor boundaries. We have developed a system to requires multiple hours, intraoperative MRI can be completed rapidly analyze and classify brain tumors based on lipid information and information evaluated within an hour. However, MRI has acquired by desorption electrospray ionization mass spectrometry limited ability to distinguish residual tumor from surrounding (DESI-MS). In this study, a classifier was built to discriminate gliomas normal brain (9). In consequence, there is a need for more de- and meningiomas based on 36 glioma and 19 meningioma samples. tailed molecular information to be acquired on a timescale closer The classifier was tested and results were validated for intraoper- to real time than can be supplied by MRI.
    [Show full text]
  • Risk-Adapted Therapy for Young Children with Embryonal Brain Tumors, High-Grade Glioma, Choroid Plexus Carcinoma Or Ependymoma (Sjyc07)
    SJCRH SJYC07 CTG# - NCT00602667 Initial version, dated: 7/25/2007, Resubmitted to CPSRMC 9/24/2007 and 10/6/2007 (IRB Approved: 11/09/2007) Activation Date: 11/27/2007 Amendment 1.0 dated January 23, 2008, submitted to CPSRMC: January 23, 2008, IRB Approval: March 10, 2008 Amendment 2.0 dated April 16, 2008, submitted to CPSRMC: April 16, 2008, (IRB Approval: May 13, 2008) Revision 2.1 dated April 29, 2009 (IRB Approved: April 30, 2009 ) Amendment 3.0 dated June 22, 2009, submitted to CPSRMC: June 22, 2009 (IRB Approved: July 14, 2009) Activated: August 11, 2009 Amendment 4.0 dated March 01, 2010 (IRB Approved: April 20, 2010) Activated: May 3, 2010 Amendment 5.0 dated July 19, 2010 (IRB Approved: Sept 17, 2010) Activated: September 24, 2010 Amendment 6.0 dated August 27, 2012 (IRB approved: September 24, 2012) Activated: October 18, 2012 Amendment 7.0 dated February 22, 2013 (IRB approved: March 13, 2013) Activated: April 4, 2013 Amendment 8.0 dated March 20, 2014. Resubmitted to IRB May 20, 2014 (IRB approved: May 22, 2014) Activated: May 30, 2014 Amendment 9.0 dated August 26, 2014. (IRB approved: October 14, 2014) Activated: November 4, 2014 Un-numbered revision dated March 22, 2018. (IRB approved: March 27, 2018) Un-numbered revision dated October 22, 2018 (IRB approved: 10-24-2018) RISK-ADAPTED THERAPY FOR YOUNG CHILDREN WITH EMBRYONAL BRAIN TUMORS, HIGH-GRADE GLIOMA, CHOROID PLEXUS CARCINOMA OR EPENDYMOMA (SJYC07) Principal Investigator Amar Gajjar, M.D. Division of Neuro-Oncology Department of Oncology Section Coordinators David Ellison, M.D., Ph.D.
    [Show full text]
  • The New WHO Classification of Brain Tumors and Molecular Profiling in the Diagnosis of Gliomas
    The New WHO Classification of Brain Tumors and Molecular Profiling in the Diagnosis of Gliomas Aivi Nguyen, MD Neuropathology Fellow Division of Neuropathology Center for Personalized Diagnosis (CPD) Glial neoplasms – infiltrating gliomas Astrocytic tumors • Diffuse astrocytoma II • Anaplastic astrocytoma III • Glioblastoma • Giant cell glioblastoma IV • Gliosarcoma Oligodendroglial tumors • Oligodendroglioma II • Anaplastic oligodendroglioma III Oligoastrocytic tumors • Oligoastrocytoma II • Anaplastic oligoastrocytoma III Courtesy of Dr. Maria Martinez-Lage 2 2016 3 The 2016 WHO classification of tumours of the central nervous system Louis et al., Acta Neuropathologica 2016 4 Talk Outline Genetic, epigenetic and metabolic changes in gliomas • Mechanisms/tumor biology • Incorporation into daily practice and WHO classification Penn’s Center for Personalized Diagnostics • Tests performed • Results and observations to date Summary 5 The 2016 WHO classification of tumours of the central nervous system Louis et al., Acta Neuropathologica 2016 6 Mechanism of concurrent 1p and 19q chromosome loss in oligodendroglioma lost FUBP1 CIC Whole-arm translocation Griffin et al., Journal of Neuropathology and Experimental Neurology 2006 7 Oligodendroglioma: 1p19q co-deletion Since the 1990s Diagnostic Prognostic Predictive Li et al., Int J Clin Exp Pathol 2014 8 Mutations of Selected Genes in Glioma Subtypes GBM Astrocytoma Oligodendroglioma Oligoastrocytoma Killela et al., PNAS 2013 9 Escaping Senescence Telomerase reverse transcriptase gene
    [Show full text]
  • Malignant CNS Solid Tumor Rules
    Malignant CNS and Peripheral Nerves Equivalent Terms and Definitions C470-C479, C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753 (Excludes lymphoma and leukemia M9590 – M9992 and Kaposi sarcoma M9140) Introduction Note 1: This section includes the following primary sites: Peripheral nerves C470-C479; cerebral meninges C700; spinal meninges C701; meninges NOS C709; brain C710-C719; spinal cord C720; cauda equina C721; olfactory nerve C722; optic nerve C723; acoustic nerve C724; cranial nerve NOS C725; overlapping lesion of brain and central nervous system C728; nervous system NOS C729; pituitary gland C751; craniopharyngeal duct C752; pineal gland C753. Note 2: Non-malignant intracranial and CNS tumors have a separate set of rules. Note 3: 2007 MPH Rules and 2018 Solid Tumor Rules are used based on date of diagnosis. • Tumors diagnosed 01/01/2007 through 12/31/2017: Use 2007 MPH Rules • Tumors diagnosed 01/01/2018 and later: Use 2018 Solid Tumor Rules • The original tumor diagnosed before 1/1/2018 and a subsequent tumor diagnosed 1/1/2018 or later in the same primary site: Use the 2018 Solid Tumor Rules. Note 4: There must be a histologic, cytologic, radiographic, or clinical diagnosis of a malignant neoplasm /3. Note 5: Tumors from a number of primary sites metastasize to the brain. Do not use these rules for tumors described as metastases; report metastatic tumors using the rules for that primary site. Note 6: Pilocytic astrocytoma/juvenile pilocytic astrocytoma is reportable in North America as a malignant neoplasm 9421/3. • See the Non-malignant CNS Rules when the primary site is optic nerve and the diagnosis is either optic glioma or pilocytic astrocytoma.
    [Show full text]
  • Meningioma ACKNOWLEDGEMENTS
    AMERICAN BRAIN TUMOR ASSOCIATION Meningioma ACKNOWLEDGEMENTS ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Meningioma Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit advocacy organization dedicated solely to brain tumor research. For nearly 45 years, the ABTA has been providing comprehensive resources that support the complex needs of brain tumor patients and caregivers, as well as the critical funding of research in the pursuit of breakthroughs in brain tumor diagnosis, treatment and care. To learn more about the ABTA, visit www.abta.org. We gratefully acknowledge Santosh Kesari, MD, PhD, FANA, FAAN chair of department of translational neuro- oncology and neurotherapeutics, and Marlon Saria, MSN, RN, AOCNS®, FAAN clinical nurse specialist, John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA; and Albert Lai, MD, PhD, assistant clinical professor, Adult Brain Tumors, UCLA Neuro-Oncology Program, for their review of this edition of this publication. This publication is not intended as a substitute for professional medical advice and does not provide advice on treatments or conditions for individual patients. All health and treatment decisions must be made in consultation with your physician(s), utilizing your specific medical information. Inclusion in this publication is not a recommendation of any product, treatment, physician or hospital. COPYRIGHT © 2017 ABTA REPRODUCTION WITHOUT PRIOR WRITTEN PERMISSION IS PROHIBITED AMERICAN BRAIN TUMOR ASSOCIATION Meningioma INTRODUCTION Although meningiomas are considered a type of primary brain tumor, they do not grow from brain tissue itself, but instead arise from the meninges, three thin layers of tissue covering the brain and spinal cord.
    [Show full text]
  • Current Diagnosis and Treatment of Oligodendroglioma
    Neurosurg Focus 12 (2):Article 2, 2002, Click here to return to Table of Contents Current diagnosis and treatment of oligodendroglioma HERBERT H. ENGELHARD, M.D., PH.D. Departments of Neurosurgery, Bioengineering, and Molecular Genetics, The University of Illinois at Chicago, Illinois Object. The strategies used to diagnose and treat oligodendroglial tumors have changed significantly over the past decade. The purpose of this paper is to review the topic of oligodendroglioma, emphasizing the new developments. Methods. Information was obtained by conducting a Medline search in which the term oligodendroglioma was used. Recent editions of standard textbooks were also studied. Because of tools such as magnetic resonance imaging, oligodendrogliomas are being diagnosed earlier, and they are being recognized more frequently histologically than in the past. Seizures are common in these patients. Functional mapping and image-guided surgery may now allow for a safer and more complete resection, especially when tumors are located in difficult areas. Genetic analysis and positron emission tomography may provide data that supplement the standard diagnostic tools. Unlike other low-grade gliomas, patients in whom residual or recurrent oligodendroglioma (World Health Organization Grade II) is present may respond to chemotherapy. Although postoperative radiotherapy prolongs survival of the patient, increasingly this therapeutic modality is being delayed until tumor recurrence, espe- cially if a gross-total tumor resection has been achieved. Oligodendrogliomas are the first type of brain tumor for which “molecular” characterization gives important information. The most significant finding is that allelic losses on chro- mosomes 1p and 19q indicate a favorable response to chemotherapy. Conclusions. Whereas surgery continues to be the primary treatment for oligodendroglioma, the scheme for post- operative therapy has shifted, primarily because of the lesion’s relative chemosensitivity.
    [Show full text]
  • Molecular Subtypes of Anaplastic Oligodendroglioma: Implications for Patient Management at Diagnosis1
    Vol. 7, 839–845, April 2001 Clinical Cancer Research 839 Molecular Subtypes of Anaplastic Oligodendroglioma: Implications for Patient Management at Diagnosis1 Yasushi Ino, Rebecca A. Betensky, without TP53 mutations, which are poorly responsive, ag- Magdalena C. Zlatescu, Hikaru Sasaki, gressive tumors that are clinically and genotypically similar David R. Macdonald, to glioblastomas. Conclusions: These data raise the possibility, for the Anat O. Stemmer-Rachamimov, first time, that therapeutic decisions at the time of diagnosis 2 David A. Ramsay, J. Gregory Cairncross, and might be tailored to particular genetic subtypes of anaplastic David N. Louis oligodendroglioma. Molecular Neuro-Oncology Laboratory, Department of Pathology and Neurosurgical Service, Massachusetts General Hospital and Harvard Medical School [Y. I., H. S., A. O. S-R., D. N. L.] and Department of INTRODUCTION Biostatistics, Harvard School of Public Health, Boston, Massachusetts Malignant gliomas are the most common type of primary 02114 [R. A. B.], and Departments of Clinical Neurological Sciences, ϳ Oncology, and Pathology, University of Western Ontario and London brain tumor, with 12,000 new cases diagnosed each year in the Regional Cancer Centre, London, Ontario N6A 4L6, Canada United States (1). For nearly a century, malignant gliomas have [M. C. Z., D. R. M., D. A. R., J. G. C.] been classified on the basis of their histological appearance as astrocytomas (including glioblastomas), oligodendrogliomas, ependymomas, or mixed gliomas. For each type, surgical resec- ABSTRACT tion and radiation therapy have been the mainstays of treatment. Purpose: In a prior study of anaplastic oligodendrogli- Cytotoxic drugs have had a relatively minor therapeutic role omas treated with chemotherapy at diagnosis or at recur- because responses to chemotherapy generally have been infre- rence after radiotherapy, allelic loss of chromosome 1p cor- quent, brief, and unpredictable.
    [Show full text]
  • Treatment and Outcome of Ganglioneuroma And
    Decarolis et al. BMC Cancer (2016) 16:542 DOI 10.1186/s12885-016-2513-9 RESEARCH ARTICLE Open Access Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed Boris Decarolis1 , Thorsten Simon1, Barbara Krug2, Ivo Leuschner3, Christian Vokuhl3, Peter Kaatsch4, Dietrich von Schweinitz5, Thomas Klingebiel6, Ingo Mueller7, Lothar Schweigerer8, Frank Berthold1 and Barbara Hero1* Abstract Background: Ganglioneuroma (GN) and ganglioneuroblastoma intermixed (GNBI) are mature variants of neuroblastic tumors (NT). It is still discussed whether incomplete resection of GN/GNBI impairs the outcome of patients. Methods: Clinical characteristics and outcome of localized GN/GNBI were retrospectively compared to localized neuroblastoma (NB) and ganglioneuroblastoma-nodular (GNBN) registered in the German neuroblastoma trials between 2000 and 2010. Results: Of 808 consecutive localized NT, 162 (20 %) were classified as GN and 55 (7 %) as GNBI. GN/GNBI patients presented more often with stage 1 disease (68 % vs. 37 %, p < 0.001), less frequently with adrenal tumors (31 % vs. 43 %, p = 0.001) and positive mIBG-uptake (34 % vs. 90 %, p < 0.001), and had less often elevated urine catecholamine metabolites (homovanillic acid 39 % vs. 62 %, p < 0.001, vanillylmandelic acid 27 % vs. 64 %, p < 0.001). Median age at diagnosis increased with grade of differentiation (NB/GNBN: 9; GNBI: 61; GN-maturing: 71; GN-mature: 125 months, p < 0.001). Complete tumor resection was achieved at diagnosis in 70 % of 162 GN and 67 % of 55 GNBI, and after 4 to 32 months of observation in 4 GN (2 %) and 5 GNBI (9 %). Eleven patients received chemotherapy without substantial effect. Fifty-five residual tumors (42 GN, 13 GNBI) are currently under observation (median: 44 months).
    [Show full text]